Oculis (NASDAQ:OCS) Sets New 1-Year High – Here’s What Happened

Oculis Holding AG (NASDAQ:OCS)’s share price reached a new 52-week high during trading on Monday . The company traded as high as $18.00 and last traded at $17.83, with a volume of 13043 shares traded. The stock had previously closed at $17.88.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Oculis in a research note on Wednesday, October 23rd. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $29.20.

Oculis Trading Down 0.2 %

The company has a market cap of $711.18 million, a price-to-earnings ratio of -9.15 and a beta of -0.16. The business’s 50 day moving average price is $13.73 and its 200-day moving average price is $12.51. The company has a current ratio of 5.27, a quick ratio of 5.27 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last issued its quarterly earnings data on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.13). The firm had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.28 million. Oculis had a negative return on equity of 61.33% and a negative net margin of 7,679.05%. On average, equities analysts anticipate that Oculis Holding AG will post -2.19 EPS for the current fiscal year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.